Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Notes Payables (2020 - 2021)

Rocket Pharmaceuticals' Notes Payables history spans 2 years, with the latest figure at $5.1 million for Q2 2021.

  • For Q2 2021, Notes Payables changed N/A year-over-year to $5.1 million; the TTM value through Jun 2021 reached $5.1 million, changed N/A, while the annual FY2020 figure was $4.9 million, N/A changed from the prior year.
  • Notes Payables for Q2 2021 was $5.1 million at Rocket Pharmaceuticals, up from $5.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $5.1 million in Q2 2021 and bottomed at $4.8 million in Q3 2020.